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A commentary on
Commentary: Efficacy of Follicle-Stimulating Hormone (FSH) Alone, FSH  +  Luteinizing 
Hormone, Human Menopausal Gonadotropin or FSH  +  Human Chorionic Gonadotropin 
on Assisted Reproductive Technology Outcomes in the “Personalized” Medicine Era: A 
Meta-Analysis
by Younis JS. Front Endocrinol (2017) 8:264. doi: 10.3389/fendo.2017.00264
We appreciated the constructive comments by Professor Younis (1) to our article (2). He gave us the 
opportunity to further discuss issues raising by the lack of clear evidence in the setting of assisted 
reproduction techniques (ART).
Although 65 meta-analyses were published so far, our study represents the first attempt to con-
sider all gonadotropin combinations currently used in clinical practice, mainly focusing on specific 
effects linked to luteinizing hormone (LH) or human choriogonadotropin (hCG) supplementation. 
The evaluation of how different therapeutic approaches impact on peculiar clinical settings, such as 
polycystic ovarian syndrome or hypo-responder women, was beyond the aims of the study. It would 
have determined a complicated stratification process, where many grouping variables would have 
been evaluated in too many undersized subgroups. Moreover, we agree with Professor Younis about 
the relevance of genetic characteristics. The polygenic nature of ovarian response implies that the 
ideal approach to controlled ovarian stimulation (COS) should be patient-specific and determined 
by genetic screening.
Recently, the Cochrane Collaboration evaluated the effect of LH addition during COS on live 
birth rate, placing no limit of age or clinical setting (3). In spite of the strict selection of randomized 
trials, the risk of selection biases remained relatively high. This was due to potential errors introduced 
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during the selection of participants, since the study groups may 
not be effectively representative of the population. Moreover, the 
method used for randomization is not clearly described in 62.1% 
of all controlled clinical trials published in the setting of ART (4). 
We decided not to consider randomization for selection, aiming 
at (I) increasing the number of potential studies to be enrolled 
and (II) reducing possible publication biases. The exclusion of 
non-randomized trials from our meta-analysis would had signifi-
cantly reduced the number of studies and of patients evaluated, 
limiting the final statistical significance of the result. Anyway, and 
as recommended by the PRISMA statement, we set strict inclu-
sion and exclusion criteria before literature search.
We agree that women’s age is an important parameter driving 
clinicians’ decision toward the best COS scheme. In our meta-
analysis, only the most important results were reported in the 
main paper, such as the type of gonadotropin-releasing hormone 
(GnRH) analog used. However, we considered age, and these 
data are reported in the supplementary materials of the original 
manuscript. In this case, a reasonable cutoff age of 35  years 
was chosen, which is an empirical matter in clinical practice 
as well. Asymmetric subdivision of studies was obtained, with 
only 17 out of 70 studies (24.3%) enrolling women with a mean 
age of >35  years. Although this cutoff could have application 
in clinical practice, it is not methodologically acceptable in a 
meta-analysis. Interestingly, we confirmed the results obtained 
in the overall analysis, when LH + FSH was compared to FSH 
alone, by considering the median value of women’s age as a cutoff 
(32.5  years). Results obtained comparing hMG vs. FSH were 
confirmed too in the group of women younger than 32.5 years. 
Taken together, these data suggest the importance of age for COS 
protocol personalization, but the empirical nature of the selected 
cutoffs is methodologically arbitrary.
In ART, women are usually characterized as poor, normo-, and 
high-responders (5). While this classification is useful for clini-
cians to choose the proper COS protocol, it could not be used 
in our research. Although several clinical trials are focused on 
poor-responder women, not all studies reported the classification 
as an inclusion criterion. Moreover, two meta-analyses compar-
ing LH + FSH vs. FSH alone in poor responders were previously 
published showing controversial results (6, 7). A debate about the 
definition of poor, normo-, and high-responders is still open, and 
different criteria were proposed (8, 9). Furthermore, concepts of 
suboptimal and hyporesponse are also emerging (10–12), but no 
trials in women accordingly selected have been published so far. 
Finally, consensus definition of poor responders is available but it 
is matter of debate and apparently not able to select homogenous 
study populations. Taken together, these observations confirm 
the weakness of this parameter both in clinical practice (13) and 
research setting.
It is common opinion that the type of GnRH analog used 
provides different residual LH activity, relying on the concept 
that <1% of LH receptors (LHCGR) occupied by the ligand 
are enough to elicit steroid synthesis (14). This is the concept 
known as “spare receptors” emerging from previous studies 
(15), often improperly handled by gynecologists to interpret 
and transpose the messages provided by in vitro studies to the 
clinics. The concept originates from the historical investigations 
of Dufau and Catt (15), who evaluated hCG-mediated cAMP 
increase and testosterone synthesis in rat Leydig cells, rather 
than human ovarian and endometrial cells treated by LH. The 
findings of such studies explained pharmacological mechanisms 
assessed exclusively in a specific context in vitro which cannot 
be used to explain clinical observations. In light of recent studies 
demonstrating fivefold lower LH- than hCG-mediated cAMP 
increase (16–18), as well as the inability of Leydig cells express-
ing rodent receptors to discriminate qualitatively intracellular 
signals mediated by the two human ligands (18), we should seri-
ously reconsider if residual LH (putative) activity is mediated 
by LHCGR in granulosa cells. LH is not as potent as hCG in 
inducing steroidogenic signals. On the other hand, LH displays 
preferential proliferative signals in human granulosa cells (19), 
not appraisable in rodents’ Leydig cells, unable to discriminate 
qualitatively between LH- and hCG-specific signals. Rather, 
residual LH activity should be due to FSH receptor-LHCGR 
heterodimers activated by FSH and mediating LH-like stimuli. 
This is also suggested by animal models: while FSH alone trig-
gers follicle maturation and ovulation in hypophysectomized 
mice, it fails to do the same in LH receptor-knockout mice 
(20). Anyway, since the residual LH activity is not routinely 
evaluated in clinical trials, this could not be considered in our 
meta-analysis.
Prof. Younis’ comments shift the interpretation of our find-
ings toward a clinical point of view, focusing on the detection of 
parameters useful to choose the best COS protocol, as a crucial 
issue for personalized medicine. However, meta-analyses fall 
short to provide guidelines or recommendations for clinical 
practice, since relying on data already published, which could 
not be directly exported to the general population. Starting from 
different activities demonstrated in vitro (16), our study aimed at 
evaluating the different action of gonadotropins in vivo, consider-
ing the COS phase as an experimental model in which to test 
these molecules. Therefore, our meta-analysis is a starting point 
to design clinical trials aimed at evaluating the best gonadotro-
pins combination for ART.
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